Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tongjitang Chinese Medicines Company has signed a definitive purchase agreement to acquire Qinghai Pulante Pharmaceutical, a privately owned plant-based pharmaceutical company.
Subscribe to our email newsletter
The company anticipates that consideration for the acquisition will be in cash, with an initial payment of approximately RMB25.5 million. Tongjitang will make additional payments over the next three years based on Pulante’s financial and operational performance. The transaction is subject to customary closing conditions and applicable regulatory approvals.
Pulante is located in Xining in the Qinghai province of China and was founded in 2000. It develops, manufactures, markets, and distributes SFDA-approved Tibetan recipe-originated medicines in China.
Xiaochun Wang, CEO and chairman of Tongjitang, said: “This transaction will further diversify our product portfolio, particularly in our OTC operating segment. We intend to drive Pulante’s sales with a focus on the COPD market, through our existing sales network and well-established distribution channels.”